July 2026 · HeydayMD Research

State of Men's Hormone Health 2026

Access gaps, at-home testing adoption, and why men's digital health is 5-10 years behind women's

40%

of men over 45 have clinically low testosterone but don't know it

$1.2B

projected US testosterone therapy market by 2027

73%

of men say they'd test hormones at home if it were easy

5-10yr

gap between women's and men's digital health investment

1. The Silent Epidemic: Most Men Don't Know Their Testosterone Levels

Testosterone deficiency affects an estimated 10-40% of adult men globally, yet the vast majority remain undiagnosed. Unlike cholesterol or blood pressure — tests that are routine parts of annual physicals — testosterone panels are rarely included in standard primary care screenings.

Key finding: The average man waits 2-3 years between first experiencing symptoms of low testosterone (fatigue, weight gain, low motivation, decreased libido) and actually getting tested. The primary barrier isn't awareness — it's access.

Traditional testosterone testing requires:

Scheduling a morning fasting blood draw (testosterone peaks early AM)
Visiting a LabCorp or Quest Diagnostics location during business hours
Waiting 3-7 days for results
Scheduling a follow-up appointment to discuss results
Often repeating the process to confirm low levels

This multi-step process creates friction at every stage — particularly for working men who can't easily take time off for morning lab appointments.

2. At-Home Diagnostics: The Access Breakthrough

At-home blood collection technology has matured significantly. Devices like the Tasso+ use microsampling to collect clinically valid blood samples from the upper arm — no venipuncture, no fasting facility visit, no time off work.

98.7%

correlation between Tasso+ microsamples and traditional venipuncture for testosterone

70%

of HeydayMD patients cite "no lab visit" as their primary reason for choosing at-home testing

The shift to at-home collection isn't just about convenience — it's fundamentally changing who gets tested. Men who would never schedule a LabCorp appointment are now testing their hormone levels because the barrier dropped from "take a morning off work" to "5 minutes at your kitchen table."

3. The Telehealth Gap in Men's Health

Women's digital health has attracted over $3B in venture funding since 2020. Companies like Maven Clinic ($300M+ raised), Kindbody ($195M), and Tia ($132M) have built comprehensive platforms for women's reproductive and hormonal health.

Men's hormone health? The landscape is fragmented:

DTC testosterone clinics — many operate as prescription mills with minimal clinical oversight
General telehealth platforms (Hims, Ro) — offer testosterone treatment but as one of dozens of product lines, not a core focus
Traditional endocrinology — excellent care but 3-6 month wait times for new patients

Key finding: There is no Maven Clinic equivalent for men's hormone health — a purpose-built digital platform with integrated diagnostics, clinical care, and ongoing monitoring. This gap is why men bounce between 2-3 providers to manage their hormone health.

4. The Pentagon Signal: Why Testosterone Screening Matters

In 2025, the U.S. Department of Defense began implementing routine testosterone screening for active-duty service members. The rationale: low testosterone affects readiness, recovery, and cognitive performance.

If the military considers testosterone important enough to screen routinely, why don't civilian primary care providers?

"The military's decision to screen for testosterone isn't about bodybuilding — it's about recognizing that hormone health is foundational to physical and mental performance. Civilian medicine should take note."

5. GLP-1 + Testosterone: The Integration Imperative

GLP-1 receptor agonists (semaglutide, tirzepatide) have become the fastest-adopted drug class in pharmaceutical history. What's less discussed: the intersection of weight loss and testosterone.

Obesity suppresses testosterone — men with BMI >30 have 30-50% lower testosterone than lean counterparts
Rapid weight loss can temporarily further suppress testosterone — creating a clinical need for monitoring
Testosterone replacement can accelerate body composition improvements — the combination may be synergistic

Key finding: Men on GLP-1 therapy need hormone monitoring. Platforms that offer both GLP-1 and testosterone management under one clinical team can provide safer, more effective care than fragmented providers.

6. What's Next: 2026-2027 Outlook

At-home testing becomes standard — within 2 years, most telehealth testosterone clinics will ship at-home kits rather than requiring lab visits
Integrated care wins — platforms offering TRT + GLP-1 + comprehensive panels under one roof will outperform single-service providers
AI-powered monitoring — longitudinal tracking of hormone levels, symptoms, and outcomes will enable personalized dosing
Insurance adoption — as at-home testing proves cost-effectiveness (fewer no-shows, faster diagnosis), payers will begin covering it
Preventive screening — following the Pentagon's lead, we expect testosterone screening to become part of standard men's wellness exams by 2028

Methodology & Sources

This report synthesizes published clinical research, market data, and platform observations from HeydayMD's patient base. Key sources include: Endocrine Society clinical practice guidelines, Grand View Research testosterone market reports, Cleveland Clinic men's health survey data, Tasso Inc. clinical validation studies, and publicly available venture funding data. Patient-level statistics are based on anonymized, aggregate HeydayMD platform data.

Get Your Testosterone Checked — From Home

HeydayMD ships at-home lab kits to your door. No lab visit, no time off work. Results in 48 hours, then a virtual visit with a licensed provider.

Take the Free Assessment →